309 related articles for article (PubMed ID: 16829574)
1. A molecular correlate to the Gleason grading system for prostate adenocarcinoma.
True L; Coleman I; Hawley S; Huang CY; Gifford D; Coleman R; Beer TM; Gelmann E; Datta M; Mostaghel E; Knudsen B; Lange P; Vessella R; Lin D; Hood L; Nelson PS
Proc Natl Acad Sci U S A; 2006 Jul; 103(29):10991-6. PubMed ID: 16829574
[TBL] [Abstract][Full Text] [Related]
2. Usual and unusual histologic patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate in needle biopsy tissue.
Gottipati S; Warncke J; Vollmer R; Humphrey PA
Am J Surg Pathol; 2012 Jun; 36(6):900-7. PubMed ID: 22367295
[TBL] [Abstract][Full Text] [Related]
3. Gene-expression analysis of gleason grade 3 tumor glands embedded in low- and high-risk prostate cancer.
Hoogland AM; Böttcher R; Verhoef E; Jenster G; van Leenders GJ
Oncotarget; 2016 Jun; 7(25):37846-37856. PubMed ID: 27191985
[TBL] [Abstract][Full Text] [Related]
4. Minimum altered regions in early prostate cancer progression identified by high resolution whole genome tiling path BAC array comparative hybridization.
Watson SK; Woolcock BW; Fee JN; Bainbridge TC; Webber D; Kinahan TJ; Lam WL; Vielkind JR
Prostate; 2009 Jun; 69(9):961-75. PubMed ID: 19267368
[TBL] [Abstract][Full Text] [Related]
5. PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer.
Imasato Y; Xuan JW; Sakai H; Izawa JI; Saito Y; Chin JL; Moussa M
J Urol; 2000 Nov; 164(5):1819-24. PubMed ID: 11025776
[TBL] [Abstract][Full Text] [Related]
6. ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63.
Torres A; Alshalalfa M; Davicioni E; Gupta A; Yegnasubramanian S; Wheelan SJ; Epstein JI; De Marzo AM; Lotan TL
Prostate; 2018 Sep; 78(12):896-904. PubMed ID: 29761525
[TBL] [Abstract][Full Text] [Related]
7. Enhanced expression of SOS1 is detected in prostate cancer epithelial cells from African-American men.
Timofeeva OA; Zhang X; Ressom HW; Varghese RS; Kallakury BV; Wang K; Ji Y; Cheema A; Jung M; Brown ML; Rhim JS; Dritschilo A
Int J Oncol; 2009 Oct; 35(4):751-60. PubMed ID: 19724911
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.
Lee CT; Capodieci P; Osman I; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
Clin Cancer Res; 1999 May; 5(5):977-83. PubMed ID: 10353729
[TBL] [Abstract][Full Text] [Related]
9. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
10. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
[TBL] [Abstract][Full Text] [Related]
11. Concordant induction of 15-lipoxygenase-1 and mutant p53 expression in human prostate adenocarcinoma: correlation with Gleason staging.
Kelavkar UP; Cohen C; Kamitani H; Eling TE; Badr KF
Carcinogenesis; 2000 Oct; 21(10):1777-87. PubMed ID: 11023533
[TBL] [Abstract][Full Text] [Related]
12. KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy.
Rabien A; Fritzsche FR; Jung M; Tölle A; Diamandis EP; Miller K; Jung K; Kristiansen G; Stephan C
Int J Cancer; 2010 Nov; 127(10):2386-94. PubMed ID: 20473923
[TBL] [Abstract][Full Text] [Related]
13. Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis.
Cheung PK; Woolcock B; Adomat H; Sutcliffe M; Bainbridge TC; Jones EC; Webber D; Kinahan T; Sadar M; Gleave ME; Vielkind J
Cancer Res; 2004 Sep; 64(17):5929-33. PubMed ID: 15342369
[TBL] [Abstract][Full Text] [Related]
14. The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up study of 648 patients treated with radiation therapy.
Zagars GK; Ayala AG; von Eschenbach AC; Pollack A
Int J Radiat Oncol Biol Phys; 1995 Jan; 31(2):237-45. PubMed ID: 7836075
[TBL] [Abstract][Full Text] [Related]
15. IgG gene expression and its possible significance in prostate cancers.
Liu Y; Chen Z; Niu N; Chang Q; Deng R; Korteweg C; Gu J
Prostate; 2012 May; 72(6):690-701. PubMed ID: 22430367
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of CD10 in prostate cancer and its clinical implication.
Dall'Era MA; True LD; Siegel AF; Porter MP; Sherertz TM; Liu AY
BMC Urol; 2007 Mar; 7():3. PubMed ID: 17335564
[TBL] [Abstract][Full Text] [Related]
17. Expression of Peroxisome Proliferator Activated Receptor gamma in Prostatic Adenocarcinoma.
Park HK; Kim H; Kim HG; Cho YM; Jung WY; Han HS; Hwang TS; Kwon GY; Lim SD
J Korean Med Sci; 2015 May; 30(5):533-41. PubMed ID: 25931782
[TBL] [Abstract][Full Text] [Related]
18. Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers.
Krohn A; Seidel A; Burkhardt L; Bachmann F; Mader M; Grupp K; Eichenauer T; Becker A; Adam M; Graefen M; Huland H; Kurtz S; Steurer S; Tsourlakis MC; Minner S; Michl U; Schlomm T; Sauter G; Simon R; Sirma H
J Pathol; 2013 Sep; 231(1):130-41. PubMed ID: 23794398
[TBL] [Abstract][Full Text] [Related]
19. A distinct repertoire of cancer-associated fibroblasts is enriched in cribriform prostate cancer.
Hesterberg AB; Rios BL; Wolf EM; Tubbs C; Wong HY; Schaffer KR; Lotan TL; Giannico GA; Gordetsky JB; Hurley PJ
J Pathol Clin Res; 2021 May; 7(3):271-286. PubMed ID: 33600062
[TBL] [Abstract][Full Text] [Related]
20. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
